Latest Pathology News

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.

Sonic Healthcare has reported a robust half-year performance, with revenue climbing 16.6% to A$5.45 billion and net profit rising 10.9%, underpinned by organic growth and key acquisitions. The company maintains its full-year guidance amid ongoing US business rationalisation.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Healius Limited reported solid half-year results for 1H26, with revenue growth driven by pathology and Agilex Biolabs, alongside significant progress in digital transformation and AI integration.

Rhythm Biosciences has inked a non-exclusive distribution agreement with 4Cyte Pathology to integrate its ColoSTAT® colorectal cancer blood test into a vast pathology network across eastern Australia, aiming to boost adoption and accessibility.

Australian Clinical Labs reported a modest revenue dip but achieved growth in earnings and margins in 1H26, while updating FY26 guidance and addressing wage increases mandated by the Fair Work Commission.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.

BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.